Administration of such nanoparticle-loaded T-cells to mice with aggressive MYC-driven lymphoma resulted in several magnitudes of improved drug uptake in tumor-bearing lymph nodes leading to tumor regression [269]. The gene discussed is MYC; the disease is neoplasm.